Cargando…
Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA)
A phase 1 dose-escalation trial assessed the chemotherapeutic potential of ammonium perfluorooctanoate (APFO). Forty-nine primarily solid-tumor cancer patients who failed standard therapy received weekly APFO doses (50–1200 mg) for 6 weeks. Clinical chemistries and plasma PFOA (anionic APFO) were me...
Autores principales: | Convertino, Matteo, Church, Timothy R, Olsen, Geary W, Liu, Yang, Doyle, Eddie, Elcombe, Clifford R, Barnett, Anna L, Samuel, Leslie M, MacPherson, Iain R, Evans, Thomas R J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920327/ https://www.ncbi.nlm.nih.gov/pubmed/29462473 http://dx.doi.org/10.1093/toxsci/kfy035 |
Ejemplares similares
-
Epidemiologic Evidence on the Health Effects of Perfluorooctanoic Acid (PFOA)
por: Steenland, Kyle, et al.
Publicado: (2010) -
Prenatal Exposure to Perfluorooctanoate (PFOA) and Perfluorooctanesulfonate (PFOS) and Maternally Reported Developmental Milestones in Infancy
por: Fei, Chunyuan, et al.
Publicado: (2008) -
Complete mineralization of perfluorooctanoic acid (PFOA) by γ-irradiation in aqueous solution
por: Zhang, Ze, et al.
Publicado: (2014) -
Serum Perfluorooctanoate (PFOA) and Perfluorooctane Sulfonate (PFOS) Concentrations and Liver Function Biomarkers in a Population with Elevated PFOA Exposure
por: Gallo, Valentina, et al.
Publicado: (2012) -
Association of Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) with Uric Acid among Adults with Elevated Community Exposure to PFOA
por: Steenland, Kyle, et al.
Publicado: (2010)